Kyprolis Wins Full Monotherapy OK, Broader Combo Use

The FDA on Jan. 21 granted Amgen Inc. approval to market Kyprolis (carfilzomib) in combination with dexamethasone or with Celgene Inc.'s Revlimid (lenalidomide) plus dexamethasone as a treatment for patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy.